• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".

作者信息

Jeyaraj Gnanaprakash

机构信息

Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Kancheepuram District, Tamil Nadu, India.

出版信息

Oral Oncol. 2024 Oct;157:106974. doi: 10.1016/j.oraloncology.2024.106974. Epub 2024 Jul 24.

DOI:10.1016/j.oraloncology.2024.106974
PMID:39053286
Abstract
摘要

相似文献

1
Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".致编辑的信，“基于日本头颈癌登记处的报告，口服细胞毒性化疗药物与放疗联合治疗T2N0声门鳞状细胞癌患者的临床益处”。
Oral Oncol. 2024 Oct;157:106974. doi: 10.1016/j.oraloncology.2024.106974. Epub 2024 Jul 24.
2
Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.基于日本头颈部癌症注册中心的报告，评估联合应用口服细胞毒性化疗药物与放疗治疗 T2N0 声门型鳞状细胞癌患者的临床获益。
Oral Oncol. 2024 Oct;157:106942. doi: 10.1016/j.oraloncology.2024.106942. Epub 2024 Jul 18.
3
Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma.对S-1同步放化疗治疗早期声门癌前瞻性研究的批判性评价。
Anticancer Res. 2015 Apr;35(4):2385-90.
4
WRAP53β, survivin and p16INK4a expression as potential predictors of radiotherapy/chemoradiotherapy response in T2N0-T3N0 glottic laryngeal cancer.WRAP53β、survivin和p16INK4a表达作为T2N0 - T3N0声门型喉癌放疗/放化疗反应的潜在预测指标
Oncol Rep. 2017 Oct;38(4):2062-2068. doi: 10.3892/or.2017.5898. Epub 2017 Aug 11.
5
Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.头颈部晚期鳞状细胞癌患者治疗相关并发症的发生率及治疗费用
Arch Otolaryngol Head Neck Surg. 2009 Jun;135(6):582-8. doi: 10.1001/archoto.2009.46.
6
Concurrent chemoradiotherapy with S-1 for T2N0 glottic squamous cell carcinoma.同步放化疗联合 S-1 治疗 T2N0 声门型鳞状细胞癌。
J Radiat Res. 2010;51(4):481-4. doi: 10.1269/jrr.09134. Epub 2010 Jun 30.
7
Radiotherapy in the management of glottic squamous cell carcinoma.声门鳞状细胞癌治疗中的放射疗法
Head Neck. 2020 Dec;42(12):3558-3567. doi: 10.1002/hed.26419. Epub 2020 Sep 8.
8
Role of concomitant chemoradiation in locally advanced head and neck cancers.同步放化疗在局部晚期头颈癌中的作用。
Asian Pac J Cancer Prev. 2014;15(10):4147-52. doi: 10.7314/apjcp.2014.15.10.4147.
9
Treatment and Survival Trends in Glottic Carcinoma in Situ and Stage I Cancer From 1988 to 2012.1988年至2012年声门原位癌和I期癌的治疗与生存趋势
Ann Otol Rhinol Laryngol. 2016 Apr;125(4):311-6. doi: 10.1177/0003489415611908. Epub 2015 Oct 19.
10
[Quality of life after simultaneous radiochemotherapy in squamous cell carcinoma of the head and neck].[头颈部鳞状细胞癌同步放化疗后的生活质量]
Strahlenther Onkol. 2000 Apr;176(4):198-200.